# Eylea Treat and Extend Protocol v1.0
# ALL parameters must be explicitly defined - no defaults allowed

name: "Eylea Treat and Extend"
version: "1.0"
created_date: "2024-01-15"
author: "Clinical Team"
description: "Standard treat-and-extend protocol for Eylea (aflibercept) based on clinical trial data"

# Protocol timing parameters (NO DEFAULTS)
protocol_type: "treat_and_extend"
min_interval_days: 28  # 4 weeks - minimum time between visits
max_interval_days: 112  # 16 weeks - maximum extension
extension_days: 14  # 2 weeks - extend by this when stable
shortening_days: 14  # 2 weeks - shorten by this when active

# Disease state transitions - all probabilities must sum to 1.0
disease_transitions:
  NAIVE:
    NAIVE: 0.0        # Cannot remain naive after first assessment
    STABLE: 0.3       # 30% achieve stability quickly
    ACTIVE: 0.6       # 60% have active disease
    HIGHLY_ACTIVE: 0.1  # 10% have severe disease
  STABLE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.85      # 85% remain stable
    ACTIVE: 0.15      # 15% develop recurrence
    HIGHLY_ACTIVE: 0.0  # Rare to jump directly to highly active
  ACTIVE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.2       # 20% achieve stability with treatment
    ACTIVE: 0.7       # 70% remain active
    HIGHLY_ACTIVE: 0.1  # 10% progress to highly active
  HIGHLY_ACTIVE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.05      # 5% achieve stability (rare)
    ACTIVE: 0.15      # 15% improve to active
    HIGHLY_ACTIVE: 0.8  # 80% remain highly active

# Treatment effect on disease transitions
# These modify the base transitions when treatment is given
treatment_effect_on_transitions:
  NAIVE:
    # No effect - naive always transitions regardless of treatment
    multipliers: {}
  STABLE:
    # Treatment helps maintain stability
    multipliers:
      STABLE: 1.1     # 10% more likely to stay stable
      ACTIVE: 0.9     # 10% less likely to become active
  ACTIVE:
    # Treatment promotes improvement
    multipliers:
      STABLE: 2.0     # Twice as likely to become stable
      ACTIVE: 0.8     # 20% less likely to stay active
      HIGHLY_ACTIVE: 0.5  # Half as likely to worsen
  HIGHLY_ACTIVE:
    # Treatment effect is limited but present
    multipliers:
      STABLE: 2.0     # Twice as likely to improve dramatically
      ACTIVE: 1.5     # 50% more likely to improve
      HIGHLY_ACTIVE: 0.75  # 25% less likely to remain severe

# Vision change model - ETDRS letter changes per visit
# All scenarios must be defined with mean and std
vision_change_model:
  naive_treated:
    mean: 0    # First visit, no change yet
    std: 1
  naive_untreated:
    mean: -2   # Untreated naive patients lose vision
    std: 2
  stable_treated:
    mean: 1    # Small improvement when stable
    std: 1
  stable_untreated:
    mean: 0    # Stable without treatment maintains
    std: 1
  active_treated:
    mean: -1   # Slight loss despite treatment
    std: 2
  active_untreated:
    mean: -3   # Significant loss without treatment
    std: 2
  highly_active_treated:
    mean: -2   # Moderate loss with treatment
    std: 2
  highly_active_untreated:
    mean: -5   # Severe loss without treatment
    std: 3

# Baseline vision distribution (ETDRS letters)
baseline_vision_distribution:
  type: normal
  mean: 70      # Typical AMD presentation
  std: 10       # Reasonable variation
  min: 20       # Legal blindness threshold
  max: 90       # Excellent vision unlikely in AMD

# Discontinuation rules - all criteria must be defined

# Clinical improvements - optional enhancements for realism
# Set enabled: true to activate all improvements
clinical_improvements:
  enabled: false
  use_loading_phase: true
  use_time_based_discontinuation: true
  use_response_based_vision: true
  use_baseline_distribution: false
  use_response_heterogeneity: true
  loading_phase_parameters:
    loading_injections: 3
    loading_interval_days: 28
  discontinuation_parameters:
    annual_probabilities:
      1: 0.125
      2: 0.15
      3: 0.12
      4: 0.08
      5: 0.075
  vision_response_parameters:
    loading:
      mean: 3.0
      std: 1.0
    year1:
      mean: 0.5
      std: 0.5
    year2:
      mean: 0.0
      std: 0.5
    year3plus:
      mean: -0.2
      std: 0.3
  response_types:
    good:
      probability: 0.3
      multiplier: 1.2
    average:
      probability: 0.5
      multiplier: 1.0
    poor:
      probability: 0.2
      multiplier: 0.6

discontinuation_rules:
  # Poor vision criteria
  poor_vision_threshold: 35        # ETDRS letters
  poor_vision_probability: 0.1     # 10% chance per visit when below threshold
  
  # High injection burden criteria  
  high_injection_count: 20         # Number of injections
  high_injection_probability: 0.02 # 2% chance per visit when above count
  
  # Long treatment duration criteria
  long_treatment_months: 36        # 3 years
  long_treatment_probability: 0.01 # 1% chance per visit after duration
  
  # Types of discontinuation
  discontinuation_types:
    - "planned"      # Patient/doctor decision
    - "adverse"      # Due to adverse events
    - "ineffective"  # Treatment not working